Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAW2020
- Development stage
- Phase 2
- Lead developer
- Brigham and Women's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DAW2020 is a small molecule drug developed by The Brigham & Women's Hospital, Inc. It is primarily indicated for the treatment of **Obstructive Sleep Apnea (OSA)**. DAW2020 acts as a hypnotic, prolonging total sleep time in OSA patients. The mechanism of action is not explicitly detailed in the available information.
- Other names
- DAW2022DAW-2022DAW 2022atomoxetine + DAW2020
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)NET (Norepinephrine Transporter)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on DAW2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAW2020.